Lack of impact of therapy on extent of Barrett's esophagus in 67 patients

Dig Dis Sci. 1990 Jan;35(1):93-6. doi: 10.1007/BF01537229.

Abstract

Sixty-seven patients with Barrett's esophagus have been prospectively followed over an average of 36 months (range 6 to 76 months) with standardized endoscopic observation and biopsies of the length of columnar epithelium. The initial length of Barrett's epithelium ranged from 1 to 16 cm, mean 5.5 cm. Specialized columnar epithelium was present in 64 of the 67 patients. Patients were treated predominantly with H2-receptor blocker therapy to relieve symptoms. Eighty-two percent of patients had less than a 1-cm change in length per year. The mean rate of change of length was -0.093 cm per year. These results confirm in a relatively large, prospective study that standard antireflux therapy for Barrett's esophagus does not result in consistent reduction in the extent of Barrett's epithelium over a three-year interval.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Barrett Esophagus / drug therapy*
  • Barrett Esophagus / pathology
  • Esophagoscopy
  • Esophagus / pathology*
  • Female
  • Follow-Up Studies
  • Histamine H2 Antagonists / therapeutic use*
  • Humans
  • Male
  • Metoclopramide / therapeutic use
  • Middle Aged
  • Prospective Studies
  • Sucralfate / therapeutic use
  • Time Factors

Substances

  • Histamine H2 Antagonists
  • Sucralfate
  • Metoclopramide